Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sofie J I Koomen

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2022
An unexplored angle: T cell antigen discoveries reveal a marginal contribution of proteasome splicing to the immunogenic MHC class I antigen poolTamara Verkerk, Sofie J I Koomen, Kyra J Fuchs, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLCEzgi B Ulas, Sofie J I Koomen, Anne Vrijmoet, et al.
Molecular Oncology|January 18, 2023
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinomaAntonio Mulero-Sánchez, Christel F A Ramirez, Aimée du Chatinier, et al.
European Journal of Immunology|December 10, 2024
Tumor-Expressed SPPL3 Supports Innate Antitumor Immune ResponsesTamara Verkerk, Antonius A de Waard, Sofie J I Koomen, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2022
An unexplored angle: T cell antigen discoveries reveal a marginal contribution of proteasome splicing to the immunogenic MHC class I antigen poolTamara Verkerk, Sofie J I Koomen, Kyra J Fuchs, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLCEzgi B Ulas, Sofie J I Koomen, Anne Vrijmoet, et al.
Molecular Oncology|January 18, 2023
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinomaAntonio Mulero-Sánchez, Christel F A Ramirez, Aimée du Chatinier, et al.
European Journal of Immunology|December 10, 2024
Tumor-Expressed SPPL3 Supports Innate Antitumor Immune ResponsesTamara Verkerk, Antonius A de Waard, Sofie J I Koomen, et al.
Pageof 1